Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ImClone Systems and Bristol-Myers Squibb have said that a phase III study of Erbitux plus gemcitabine in patients with pancreatic cancer did not meet its primary endpoint of improving overall survival.
Subscribe to our email newsletter
The study was conducted by the Southwest Oncology Group (SWOG), a cancer center network sponsored by the National Cancer Institute. SWOG will engage with ImClone and Bristol-Myers Squibb in order to examine the data in more detail.
“We still consider pancreatic cancer to be of the utmost priority and we intend to pursue additional evaluations with Erbitux including a pilot study of Erbitux and bevacizumab with or without gemcitabine, as well as our pipeline agents, to improve the outcome for patients with pancreatic cancer.” stated Eric Rowinsky, senior vice president of ImClone Systems.
Erbitux is already approved to treat colorectal cancer and head and neck cancer and is the only approved product in ImClone's pipeline.